MRG-001 for severe lung injury (ARDS)
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new medicine called MRG-001 for people with severe lung injury (ARDS) who need breathing support. It aims to help the lungs heal and reduce inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with ARDS and are on a breathing machine or high-flow oxygen.
- You are not on life support like ECMO or a high-frequency ventilator.
- You do not have a weakened immune system from disease or medications.
- You are not pregnant or breastfeeding.
- You do not have severe pre-existing organ failure (e.g., heart, kidney, liver).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LEAF-4L6715 to see if it helps people with severe acute respiratory distress syndrome (ARDS), a serious lung condition. If you are on a breathing machine and meet the criteria below, you may be able to join.
This trial tests a new drug (R-3750) given by mouth through a feeding tube for patients with severe lung injury (ARDS) that hasn't improved after one to four weeks of intensive care. The goal is to see if the drug helps patients recover better.
This Phase 2 trial tests Rhu-pGSN in adults with acute respiratory distress syndrome (ARDS) caused by an infection. If you qualify, the study may help determine whether the drug improves outcomes in this short-term, life-threatening lung condition.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This pilot study tests NOA-001, a treatment given to people with ARDS (a serious lung condition) who are already on a breathing machine. It looks at whether the treatment can improve outcomes in ARDS caused by either non-COVID illnesses or COVID-19.
This study tests if adding a type of steroid (glucocorticoid) to standard treatment helps people on a breathing machine recover from severe lung failure (ARDS). It compares different doses to see which works best.
Hear when a new Acute Respiratory Distress Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.